Legal & General Group
LRMR icon

Legal & General Group’s Larimar Therapeutics LRMR Stock Holding History

Legal & General Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6K Sell
3,691
-1,163
-24% -$4.65K ﹤0.01% 3033
2025
Q4 		$18.5K Buy
4,854
+243
+5% +$945 ﹤0.01% 3061
2025
Q3 		$14.9K Buy
4,611
+980
+27% +$3.67K ﹤0.01% 3169
2025
Q2 		$10.5K Sell
3,631
-6,087
-63% -$14.1K ﹤0.01% 3277
2025
Q1 		$20.9K Hold
9,718
– – ﹤0.01% 2925
2024
Q4 		$37.6K Buy
9,718
+1,659
+21% +$11K ﹤0.01% 2831
2024
Q3 		$52.8K Sell
8,059
-140
-2% -$1.13K ﹤0.01% 2785
2024
Q2 		$59.4K Buy
8,199
+6,094
+290% +$46.7K ﹤0.01% 2772
2024
Q1 		$16K Sell
2,105
-376
-15% -$2.93K ﹤0.01% 3057
2023
Q4 		$11.3K Hold
2,481
– – ﹤0.01% 3207
2023
Q3 		$9.79K Hold
2,481
– – ﹤0.01% 3273
2023
Q2 		$7.77K Buy
+2,481
New +$10.1K ﹤0.01% 3343
2019
Q3 		– Sell
-380
Closed -$5K – 3393
2019
Q2 		$5K Hold
380
– – ﹤0.01% 3445
2019
Q1 		$12K Hold
380
– – ﹤0.01% 3218
2018
Q4 		$23K Hold
380
– – ﹤0.01% 3026
2018
Q3 		$53K Buy
380
+97
+34% +$11.8K ﹤0.01% 2745
2018
Q2 		$35K Buy
+283
New +$24K ﹤0.01% 2930
2017
Q2 		– Sell
-584
Closed -$32K – 3370
2017
Q1 		$32K Buy
584
+125
+27% +$6.21K ﹤0.01% 2961
2016
Q4 		$18K Buy
459
+217
+90% +$8.8K ﹤0.01% 3134
2016
Q3 		$9K Hold
242
– – ﹤0.01% 2850
2016
Q2 		$17K Hold
242
– – ﹤0.01% 2861
2016
Q1 		$19K Hold
242
– – ﹤0.01% 2674
2015
Q4 		$18K Hold
242
– – ﹤0.01% 2717
2015
Q3 		$93K Hold
242
– – ﹤0.01% 2078
2015
Q2 		$100K Buy
242
+137
+130% +$57.3K ﹤0.01% 2112
2015
Q1 		$51K Buy
+105
New +$49.8K ﹤0.01% 2480

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Legal & General Group's LRMR Position: Q1 2026 in Review

Legal & General Group reduced its Larimar Therapeutics (LRMR) stake by 24% in Q1 2026, selling an estimated $4.65K and leaving 3,691 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

Legal & General Group first reported a position in LRMR in Q1 2015 and has held it in 26 quarters since. The position peaked at $100K in Q2 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Legal & General Group held 3,691 shares of Larimar Therapeutics worth $16.6K as of Q1 2026.
  • Legal & General Group sold 1,163 Larimar Therapeutics shares in Q1 2026, an estimated $4.65K.
  • Larimar Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3033 holding.
  • Legal & General Group first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 26 quarters since.
  • Legal & General Group's Larimar Therapeutics position peaked at $100K in Q2 2015.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.